Patents Assigned to Mucosis B.V.
-
Patent number: 9878034Abstract: The invention relates to adjuvanted vaccine formulations, in particular influenza vaccines for intranasal delivery. Provided is an adjuvanted influenza vaccine formulation, comprising (i) peptidoglycan microparticles obtained from a Gram-positive bacterium and (ii) at least one influenza virus antigen or antigenic preparation thereof, which antigen or antigenic preparation is not fused or otherwise covalently attached to a proteinaceous peptidoglycan binding moiety.Type: GrantFiled: October 1, 2010Date of Patent: January 30, 2018Assignee: MUCOSIS B.V.Inventors: Govert Johan Schouten, Cornelis Johannes Leenhouts
-
Patent number: 9585953Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.Type: GrantFiled: March 22, 2012Date of Patent: March 7, 2017Assignee: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria de Haan, Berend Jan Bosch
-
Patent number: 9549974Abstract: The invention relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunization against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunization against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: GrantFiled: February 15, 2012Date of Patent: January 24, 2017Assignee: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Publication number: 20140093532Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.Type: ApplicationFiled: March 22, 2012Publication date: April 3, 2014Applicant: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus Van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria De Haan, Berend Jan Bosch
-
Publication number: 20120301501Abstract: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: ApplicationFiled: February 15, 2012Publication date: November 29, 2012Applicant: MUCOSIS B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Patent number: 8142789Abstract: The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgAl proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis.Type: GrantFiled: May 17, 2004Date of Patent: March 27, 2012Assignee: Mucosis B.V.Inventors: Cornelis Johannes Leenhouts, Ronald de Groot, Peter Wilhelmus Maria Hermans
-
Patent number: RE47471Abstract: Heat-stable oligomeric recombinant polypeptides, presenting at least one antigenic epitope of the pre-fusion Respiratory Syncytial Virus (RSV) F protein, comprising the RSV F protein ectodomain, functionally deleted in the HRB region, transmembrane and cytoplasmic domains replaced with a heterologous trimerization domain, and absent two functional multibasic furin cleavage sites, are useful as antigenic components in immunogenic compositions useful in methods of inducing an immune response and vaccinate against RSV infections.Type: GrantFiled: March 26, 2016Date of Patent: July 2, 2019Assignee: Mucosis B.V.Inventors: Cornelis Alexander Maria de Haan, Petrus Josephus Marie Rottier, Bert Jan Haijema